Use of ivacaftor in late diagnosed cystic fibrosis monozygotic twins heterozygous for F508del and R117H-7T – a case report
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Use of ivacaftor in late diagnosed cystic fibrosis monozygotic twins heterozygous for F508del and R117H-7T – a case report
Authors
Keywords
Cystic fibrosis, Monogenetic twins, Heterozygous, F508del, R117H-7T, Elderly, Late diagnosis, Ivacaftor
Journal
BMC Pulmonary Medicine
Volume 19, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-04-11
DOI
10.1186/s12890-019-0840-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Disease-modifying genetic factors in cystic fibrosis
- (2018) Fernando A.L. Marson CURRENT OPINION IN PULMONARY MEDICINE
- Precision Medicine In Action: The Impact Of Ivacaftor On Cystic Fibrosis–Related Hospitalizations
- (2018) Lisa B. Feng et al. HEALTH AFFAIRS
- Lung function decline is delayed but not decreased in patients with cystic fibrosis and the R117H gene mutation
- (2018) Jeffrey S. Wagener et al. Journal of Cystic Fibrosis
- Intra-individual biological variation in sweat chloride concentrations in CF, CFTR dysfunction, and healthy pediatric subjects
- (2018) Natalia Cirilli et al. PEDIATRIC PULMONOLOGY
- Phenotypic spectrum of patients with cystic fibrosis and cystic fibrosis-related disease carrying p.Arg117His
- (2018) Katherine Keenan et al. Journal of Cystic Fibrosis
- SLC26A9 Gene Is Associated With Lung Function Response to Ivacaftor in Patients With Cystic Fibrosis
- (2018) Harriet Corvol et al. Frontiers in Pharmacology
- Changes of CFTR functional measurements and clinical improvements in cystic fibrosis patients with non p.Gly551Asp gating mutations treated with ivacaftor
- (2017) Myriam Mesbahi et al. Journal of Cystic Fibrosis
- Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation
- (2017) Philip M. Farrell et al. JOURNAL OF PEDIATRICS
- Thirty Years of Sweat Chloride Testing at One Referral Center
- (2017) Alethéa Guimarães Faria et al. Frontiers in Pediatrics
- Forecasting US ivacaftor outcomes and cost in cystic fibrosis patients with the G551D mutation
- (2016) Piyameth Dilokthornsakul et al. EUROPEAN RESPIRATORY JOURNAL
- Phenotypic variability of R117H-CFTR expression within monozygotic twins
- (2016) Michael D. Waller et al. Paediatric Respiratory Reviews
- Classification of CFTR mutation classes
- (2016) Fernando Augusto Lima Marson et al. Lancet Respiratory Medicine
- Efficacy response in CF patients treated with ivacaftor: Post-hoc analysis
- (2015) Michael W. Konstan et al. PEDIATRIC PULMONOLOGY
- Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial
- (2015) Richard B Moss et al. Lancet Respiratory Medicine
- Effects of Ivacaftor in Patients With Cystic Fibrosis Who Carry the G551D Mutation and Have Severe Lung Disease
- (2014) Peter J. Barry et al. CHEST
- Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis
- (2014) Penny Whiting et al. HEALTH TECHNOLOGY ASSESSMENT
- Lung disease modifier genes in cystic fibrosis
- (2014) Loic Guillot et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation
- (2014) Kris De Boeck et al. Journal of Cystic Fibrosis
- Change in Sweat Chloride as a Clinical End Point in Cystic Fibrosis Clinical Trials
- (2013) Anthony G. Durmowicz et al. CHEST
- How genetic modifiers influence the phenotype of spinal muscular atrophy and suggest future therapeutic approaches
- (2013) Brunhilde Wirth et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551D mutation
- (2013) Helge Hebestreit et al. Journal of Cystic Fibrosis
- Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function
- (2013) Fredrick Van Goor et al. Journal of Cystic Fibrosis
- Sweat chloride is not a useful marker of clinical response to Ivacaftor
- (2013) Peter J Barry et al. THORAX
- Understanding the natural progression in %FEV1decline in patients with cystic fibrosis: a longitudinal study
- (2012) David Taylor-Robinson et al. THORAX
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutation
- (2011) Bonnie W. Ramsey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTRMutation
- (2010) Frank J. Accurso et al. NEW ENGLAND JOURNAL OF MEDICINE
- The very low penetrance of cystic fibrosis for the R117H mutation: a reappraisal for genetic counselling and newborn screening
- (2009) C Thauvin-Robinet et al. JOURNAL OF MEDICAL GENETICS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started